The phase 1/2b clinical trial on R21/Matrix-M malaria vaccine has recently reported the safety and efficacy of booster vaccination at 12 months. The entire report has been published in The Lancet ...

Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...

Matrix-M is Novavax’s proprietary adjuvant technology used to enhance immune response in vaccines. The company noted that this agreement, along with other recently formed partnerships, demonstrates ...

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...

Novavax is shifting to a partnership-driven strategy, focusing on its Matrix-M adjuvant platform to enhance immune responses and reduce costs. The company aims for non-GAAP profitability by 2028, ...

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

At the J. P. Morgan Healthcare Conference 2026, Novavax’s President and CEO, John C. Jacobs, reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond. From a ...